ChemicalBook

Lapatinib ditosylate

 структура
388082-78-8
CAS №
388082-78-8
английское имя:
Lapatinib ditosylate
Синонимы:
Lapatinib ditosylate Monohydrate;Lapatinib tosilate;Lapatinib ditosylate hydrate;Lapatinb;GW2016 ditosylate;GW-572016;GW572016;(E)-Ferulic acid-d;lapatinib(GW572016);Lapatinib Ditosilate;Lapatinib ditosylate
CBNumber:
CB2966227
Формула:
C41H40ClFN4O11S3
молекулярный вес:
925.46
MOL File:
388082-78-8.mol

Lapatinib ditosylate атрибут

Температура плавления: >200oC (dec.)
температура хранения: under inert gas (nitrogen or Argon) at 2-8°C
растворимость: ДМСО (Мало растворим), метанол (Мало растворим)
форма: Твердый
цвет: Желтый
Справочник по базе данных CAS: 388082-78-8(CAS DataBase Reference)
FDA UNII: G873GX646R
Словарь онкологических терминов NCI: lapatinib ditosylate
Словарь наркотиков NCI: lapatinib ditosylate
безопасность
  • Заявления о рисках и безопасности
  • код информации об опасности(GHS)
символ(GHS)
сигнальное слово
Заявление об опасности
пароль Заявление об опасности Класс опасности категория сигнальное слово пиктограмма предупреждение
H413 Может вызвать долгосрочные отрицательные последствия для водных организмов. Опасность для водной среды, долгосрочная опасность Категория 4
Внимание

Lapatinib ditosylate химические свойства, назначение, производство

Использование

Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-?2 inhibitor.

Общее описание

Lapatinib is available in 250-mg tablets for oral administrationand is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of <0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t1/2=300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.There have been reports of decreases in left ventricularejection fraction associated with the agent, although thisappears to occur only rarely and is reversible upon discontinuationof therapy.

Lapatinib ditosylate препаратная продукция и сырье

сырьё

препарат


Lapatinib ditosylate поставщик

Global( 266)Suppliers
поставщик телефон страна номенклатура продукции благоприятные условия
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
+86-18600796368 +86-18600796368
China 74 58
Apeloa production Co.,Limited
+8619933239880
China 853 58
hebei hongtan Biotechnology Co., Ltd
+86-86-1913198-3935 +8617331935328
China 973 58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.
+86-0531-69954981 +8615666777973
China 211 58
Hebei Fengjia New Material Co., Ltd
+86-0311-87836622 +86-17333973358
China 15695 58
Hebei Yanxi Chemical Co., Ltd.
+86-17531190177; +8617531190177
China 6011 58
Hebei Mojin Biotechnology Co., Ltd
+86 13288715578 +8613288715578
China 12459 58
Amadis Chemical Company Limited
571-89925085
China 131980 58
Shanghai Likang New Materials Co., Limited
+86-16631818819 +86-17736933208
China 9311 58
Wuhan Jingkang en Biomedical Technology Co., Ltd
+8613720134139
China 4692 58
Copyright 2017 © ChemicalBook. All rights reserved